Clinical Trials Of MVA-EBNA1/LMP2, A Therapeutic Cancer Vaccine Designed To Treat Epstein-Barr Virus (EBV) Positive NasopharyngealCarcinoma (NPC)
Session type: Parallel sessions
Most nasopharyngeal carcinoma (NPC) carry Epstein-Barr Virus (EBV) and consistently express two viral proteins, EB nuclear antigen 1 (EBNA1) and latent membrane protein 2 (LMP2). These proteins represent ideal targets for immunotherapy. MVA-EBNA1/LMP2 is an attenuated poxvirus-based therapeutic cancer vaccine designed to boost T cell immunity to these EBV-encoded tumour antigens in NPC patients.